Cargando…

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia

JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed a screening for JAK2 mutations and translocations, analyzed the clinical outcome and studied the efficacy of two JAK inhibitors in pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steeghs, Elisabeth M.P., Jerchel, Isabel S., de Goffau-Nobel, Willemieke, Hoogkamer, Alex Q., Boer, Judith M., Boeree, Aurélie, van de Ven, Cesca, Koudijs, Marco J., Besselink, Nicolle J.M., de Groot-Kruseman, Hester A., Zwaan, Christian Michel, Horstmann, Martin A., Pieters, Rob, den Boer, Monique L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685720/ https://www.ncbi.nlm.nih.gov/pubmed/29163799 http://dx.doi.org/10.18632/oncotarget.21027

Ejemplares similares

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia
por: Jerchel, I S, et al.
Publicado: (2018)

Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia
por: Jerchel, Isabel S., et al.
Publicado: (2019)

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2019)

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2018)

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
por: Boer, Judith M., et al.
Publicado: (2016)

Ibrutinib is not an effective drug in primografts of TCF3-PBX1
por: van de Ven, Cesca, et al.
Publicado: (2020)

Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line
por: van Outersterp, Inge, et al.
Publicado: (2023)

Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
por: Hormann, Femke M., et al.
Publicado: (2023)

Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015
por: Reedijk, Ardine M. J., et al.
Publicado: (2020)

S112: THE EFFECT OF IMMUNOGLOBULIN PROPHYLAXIS ON INFECTIOUS MORBIDITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A RANDOMIZED CONTROLLED TRIAL
por: Thus, Kirsten, et al.
Publicado: (2023)

Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis
por: Klaassen, Irene L. M., et al.
Publicado: (2019)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

High Prevalence of Constitutional Mismatch Repair Deficiency in a Pediatric T-cell Lymphoblastic Lymphoma Cohort
por: Kroeze, Emma, et al.
Publicado: (2021)

Effect of post-consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols
por: van Atteveld, Jenneke E., et al.
Publicado: (2021)

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
por: Østergaard, Anna, et al.
Publicado: (2023)

In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
por: Klumper, E., et al.
Publicado: (1995)

Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
por: Roncero, A M, et al.
Publicado: (2016)

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia
por: van der Veer, A, et al.
Publicado: (2014)

Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
por: Michels, Naomi, et al.
Publicado: (2021)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

PKCζ and PKMζ are overexpressed in TCF3-rearranged paediatric acute lymphoblastic leukaemia and are associated with increased thiopurine sensitivity
por: Hartsink-Segers, S A, et al.
Publicado: (2015)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

P316: PRIORITIZING PRECISION MEDICINES IN PEDIATRIC BLOOD CANCER: EXPERIENCE OF THE DUTCH INDIVIDUALIZED THERAPY (ITHER) STUDY’S MOLECULAR TUMOR BOARD
por: Boer, Judith M., et al.
Publicado: (2023)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia
por: de Bock, Charles E., et al.
Publicado: (2018)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
por: Scheijen, Blanca, et al.
Publicado: (2017)

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
por: Flex, Elisabetta, et al.
Publicado: (2008)

Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia
por: Polak, Roel, et al.
Publicado: (2019)

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2015)

P425: A MULTIDIMENSIONAL AND SPATIAL ANALYSIS REVEALS DISTINCT IMMUNE PHENOTYPES AND SECONDARY LYMPHOID ORGAN-RESEMBLING STRUCTURES IN THE BONE MARROW OF PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Koedijk, Joost, et al.
Publicado: (2023)

Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome
por: Witkowski, Matthew T., et al.
Publicado: (2017)

JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia
por: Bodaar, Kimberly, et al.
Publicado: (2022)

Should new health technology be available only for patients able and willing to pay?
por: Calcoen, Piet, et al.
Publicado: (2017)

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
por: Forero-Castro, Maribel, et al.
Publicado: (2017)

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017)

Substitution of care for chronic heart failure from the hospital to the general practice: patients’ perspectives
por: Wildeboer, J. A., et al.
Publicado: (2018)

Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone
por: Warris, Lidewij T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4r2olgji116b3ramq2sj97nkpl